Merus N.V. MRUS
We take great care to ensure that the data presented and summarized in this overview for Merus N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRUS
View all-
Wellington Management Group LLP Boston, MA4.72MShares$290 Million0.04% of portfolio
-
Commodore Capital LP New York, NY4.47MShares$275 Million18.43% of portfolio
-
Rtw Investments, LP New York, NY4.17MShares$256 Million2.88% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.37MShares$207 Million7.27% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.17MShares$195 Million3.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$184 Million2.04% of portfolio
-
Samlyn Capital, LLC New York, NY2.38MShares$146 Million1.65% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$122 Million0.03% of portfolio
-
Holocene Advisors, LP New York, NY1.87MShares$115 Million0.25% of portfolio
-
Polar Capital Holdings PLC London, X01.71MShares$105 Million0.48% of portfolio
Latest Institutional Activity in MRUS
Top Purchases
Top Sells
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Insider Transactions at MRUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$1,500,000
$60.0 P/Share
|
|
Jul 17
2025
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$600,000
$24.43 P/Share
|
|
Jul 10
2025
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
16,805
-100.0%
|
$924,275
$55.0 P/Share
|
|
Jul 10
2025
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
16,805
+50.0%
|
$302,490
$18.61 P/Share
|
|
Jul 09
2025
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
6,695
-100.0%
|
$368,225
$55.0 P/Share
|
|
Jul 09
2025
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
6,695
+50.0%
|
$120,510
$18.61 P/Share
|
|
Jun 20
2025
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
34,000
-100.0%
|
$1,768,000
$52.76 P/Share
|
|
Jun 20
2025
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+50.0%
|
$612,000
$18.61 P/Share
|
|
Apr 17
2025
|
Sven Ante Lundberg President, CEO & PEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,297
+48.33%
|
$393,861
$13.03 P/Share
|
|
Mar 21
2025
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
4,000
-14.16%
|
$192,000
$48.51 P/Share
|
|
Mar 21
2025
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+9.37%
|
-
|
|
Feb 19
2025
|
Sven Ante Lundberg President, CEO & PEO |
BUY
Bona fide gift
|
Indirect |
40,601
+50.0%
|
-
|
|
Feb 19
2025
|
Sven Ante Lundberg President, CEO & PEO |
SELL
Bona fide gift
|
Direct |
40,601
-100.0%
|
-
|
|
Feb 13
2025
|
Sven Ante Lundberg President, CEO & PEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,372
+28.74%
|
$392,928
$24.43 P/Share
|
|
Jan 01
2025
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+29.41%
|
-
|
|
Aug 21
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
2,500
-26.31%
|
$135,000
$54.0 P/Share
|
|
Aug 21
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+20.83%
|
-
|
|
Aug 20
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
2,500
-26.31%
|
$135,000
$54.0 P/Share
|
|
Aug 20
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+20.83%
|
-
|
|
Jun 27
2024
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$600,000
$60.0 P/Share
|
Last 12 Months Summary
| Bona fide gift | 40.6K shares |
|---|---|
| Exercise of conversion of derivative security | 142K shares |
| Bona fide gift | 40.6K shares |
|---|---|
| Open market or private sale | 91.5K shares |